← All trials
NCT04614610
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 2, 2020
- Primary completion
- Nov 2, 2021
- Completion date
- Feb 1, 2022
- First posted
- Nov 4, 2020
- Last posted
- Nov 4, 2020
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Community Medical Center, Toms River, NJLead sponsor
- St. Barnabas Medical Center, Livingston, NJCollaborator
- Newark Beth Israel Medical CenterCollaborator
- Community Medical Center, Toms River, NJReponsible party - principal investigator
- Newark Beth Israel Medical CenterOverall official - principal investigator
- Monmouth Medical CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.